

An update on the HI-Light Vitiligo Trial - two years on...

Many of you have been following the progress of the HI-Light trial through *Dispatches* over the last few years, and we thank you all for your incredible support. We thought you'd like to know that the trial has now finished recruiting participants, with an impressive 517 people taking part in the trial (including 119 children).

Of course, it is not over yet. We are now following everyone over the course of their treatments to see how well the vitiligo responds. The HI-Light trial is also unusual in that it is following participants for a further 12 months after they stop using their treatments, to see how well the treatments work in the longer term.

The overwhelming interest in this study has proven beyond doubt that there is a large unmet need to find effective vitiligo treatments for people with vitiligo. We don't yet know whether the treatments being compared have worked, but the HI-Light trial is one of just a handful of trials around the world that is sufficiently well designed to guide clinical decision-making, and we are all very much looking forward to finding out the results in due course.

If all goes well, we hope to be able to share the results with you all in early 2020.

What is the HI-Light Vitiligo Trial about?

Treatments being compared:

- Corticosteroid ointment (mometasone furoate)
- Hand-held narrowband UVB light therapy (used at home)
- Both treatments used together

Who is taking part?

- Adults and children (aged over 5 years) with vitiligo patches that have newly appeared or changed in size over the last 12 months

How long is the study?

- Participants use their vitiligo treatments for 9 months (or until the vitiligo has gone)
- Once the treatment has been stopped, participants continue to answer questionnaires for a further 12 months to see how long the treatment response last for.

How will we know if the treatments have worked?

- The number of participants with "treatment success" after 9 months of treatment will be compared for the three groups
- Treatment success is being assessed on the basis of how noticeable the vitiligo is compared to before treatment.

The HI-Light Vitiligo trial is funded by the National Institute for Health Research's Health Technology Assessment Programme (project number 12/24/02) to inform NHS care. The views and opinions expressed herein are those of the HI-Light Vitiligo Trial Management team and do not necessarily reflect those of National Institute for Health Research's HTA Programme, NIHR, NHS or the Department of Health.